Download PDFPDF
Utility of admission cardiac troponin and “Ischemia Modified Albumin” measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Is “Ischemia Modified Albumin” an early diagnostic indicator of myocardial infarction?
    • cenker eken, attending physcian
    • Other Contributors:
      • Yildiray Cete, Oktay Eray

    Dear Editor,

    I would like to thank Dr Collinson (1) for his article about the utility of ischemia modified albumin (IMA) in chest pain patients. However the results may be overstated regarding IMA in patients with chest pain, particularly in patients with acute myocardial infarction (AMI).

    First of all excluding ST segment elevation MI patients could create a selection bias. Because some of these patients ha...

    Show More
    Conflict of Interest:
    None declared.